- Home
- IMCR vs MD Comparison
IMCR vs MD Comparison
Compare IMCR & MD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- MD
- Stock Information
- Founded
- IMCR 2008
- MD 1979
- Country
- IMCR United Kingdom
- MD United States
- Employees
- IMCR N/A
- MD N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- MD Hospital/Nursing Management
- Sector
- IMCR Health Care
- MD Health Care
- Exchange
- IMCR Nasdaq
- MD Nasdaq
- Market Cap
- IMCR 1.4B
- MD 1.2B
- IPO Year
- IMCR 2021
- MD 1995
- Fundamental
- Price
- IMCR $28.41
- MD $12.82
- Analyst Decision
- IMCR Buy
- MD Buy
- Analyst Count
- IMCR 12
- MD 6
- Target Price
- IMCR $60.90
- MD $16.75
- AVG Volume (30 Days)
- IMCR 403.7K
- MD 753.5K
- Earning Date
- IMCR 05-07-2025
- MD 05-06-2025
- Dividend Yield
- IMCR N/A
- MD N/A
- EPS Growth
- IMCR N/A
- MD N/A
- EPS
- IMCR N/A
- MD N/A
- Revenue
- IMCR $310,202,000.00
- MD $2,012,919,000.00
- Revenue This Year
- IMCR $20.52
- MD N/A
- Revenue Next Year
- IMCR $8.57
- MD $2.76
- P/E Ratio
- IMCR N/A
- MD N/A
- Revenue Growth
- IMCR 24.36
- MD 0.92
- 52 Week Low
- IMCR $23.15
- MD $6.62
- 52 Week High
- IMCR $62.74
- MD $17.67
- Technical
- Relative Strength Index (RSI)
- IMCR 51.56
- MD 37.12
- Support Level
- IMCR $26.37
- MD $12.96
- Resistance Level
- IMCR $27.67
- MD $13.60
- Average True Range (ATR)
- IMCR 1.76
- MD 0.62
- MACD
- IMCR 0.10
- MD -0.11
- Stochastic Oscillator
- IMCR 77.93
- MD 2.40
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About MD Pediatrix Medical Group Inc.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.